These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 19620338

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression.
    Rose WE, Fallon M, Moran JJ, Vanderloo JP.
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4422-7. PubMed ID: 22687502
    [Abstract] [Full Text] [Related]

  • 5. [Investigation of antibiotic resistance patterns and reduced vancomycin susceptibilities of methicillin-resistant Staphylococcus aureus isolates: a multi-center study].
    Çıkman A, Aydın M, Gülhan B, Parlak M, Gültepe B, Kalaycı Y, Bayındır Bilmen F, Solmaz S, Özekinci T.
    Mikrobiyol Bul; 2015 Apr; 49(2):240-8. PubMed ID: 26167824
    [Abstract] [Full Text] [Related]

  • 6. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR, Barber KE, Hallesy J, Raut A, Rybak MJ.
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [Abstract] [Full Text] [Related]

  • 7. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
    Jevitt LA, Smith AJ, Williams PP, Raney PM, McGowan JE, Tenover FC.
    Microb Drug Resist; 2003 Sep; 9(4):389-93. PubMed ID: 15000746
    [Abstract] [Full Text] [Related]

  • 8. Unmasking a looming crisis: Escalating MIC of last resort drugs against MRSA isolates from a tertiary care hospital in Central India.
    Bawankar NS, Agrawal GN, Zodpey Shrikhande SS.
    Indian J Med Microbiol; 2024 Sep; 51():100707. PubMed ID: 39173910
    [Abstract] [Full Text] [Related]

  • 9. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
    Karlowsky JA, Nichol K, Zhanel GG.
    Clin Infect Dis; 2015 Sep 15; 61 Suppl 2():S58-68. PubMed ID: 26316559
    [Abstract] [Full Text] [Related]

  • 10. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
    Rybak MJ, Hershberger E, Moldovan T, Grucz RG.
    Antimicrob Agents Chemother; 2000 Apr 15; 44(4):1062-6. PubMed ID: 10722513
    [Abstract] [Full Text] [Related]

  • 11. Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008).
    Mendes RE, Sader HS, Jones RN.
    Int J Antimicrob Agents; 2010 Oct 15; 36(4):374-9. PubMed ID: 20598860
    [Abstract] [Full Text] [Related]

  • 12. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
    Bogdanovich T, Esel D, Kelly LM, Bozdogan B, Credito K, Lin G, Smith K, Ednie LM, Hoellman DB, Appelbaum PC.
    Antimicrob Agents Chemother; 2005 Aug 15; 49(8):3325-33. PubMed ID: 16048943
    [Abstract] [Full Text] [Related]

  • 13. Comparative activity of oritavancin against meticillin-resistant Staphylococcus aureus (MRSA) bloodstream isolates from Geneva University Hospital.
    Vaudaux P, Huggler E, Arhin FF, Moeck G, Renzoni A, Lew DP.
    Int J Antimicrob Agents; 2009 Dec 15; 34(6):540-3. PubMed ID: 19744838
    [Abstract] [Full Text] [Related]

  • 14. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
    Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF.
    Antimicrob Agents Chemother; 2008 Jul 15; 52(7):2383-8. PubMed ID: 18443115
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.
    McMullen AR, Lainhart W, Wallace MA, Shupe A, Burnham CD.
    Eur J Clin Microbiol Infect Dis; 2019 Dec 15; 38(12):2323-2330. PubMed ID: 31446513
    [Abstract] [Full Text] [Related]

  • 16. Resistance selection studies comparing the activity of razupenem (PTZ601) to vancomycin and linezolid against eight methicillin-resistant and two methicillin-susceptible Staphylococcus aureus strains.
    Clark C, Kosowska-Shick K, McGhee P, Dewasse B, Beachel L, Appelbaum PC.
    Antimicrob Agents Chemother; 2009 Jul 15; 53(7):3118-21. PubMed ID: 19433566
    [Abstract] [Full Text] [Related]

  • 17. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
    Leuthner KD, Cheung CM, Rybak MJ.
    J Antimicrob Chemother; 2006 Aug 15; 58(2):338-43. PubMed ID: 16787952
    [Abstract] [Full Text] [Related]

  • 18. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
    Crandon JL, Kuti JL, Nicolau DP.
    Antimicrob Agents Chemother; 2010 Dec 15; 54(12):5115-9. PubMed ID: 20837760
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of telavancin and comparator antimicrobial agents against a panel of genetically defined staphylococci.
    Farrell DJ, Krause KM, Benton BM.
    Diagn Microbiol Infect Dis; 2011 Mar 15; 69(3):275-9. PubMed ID: 21353951
    [Abstract] [Full Text] [Related]

  • 20. In vitro activity of meropenem/piperacillin/tazobactam triple combination therapy against clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus pseudintermedius and vancomycin-resistant Enterococcus spp.
    Yoneda A, Thänert R, Burnham CD, Dantas G.
    Int J Antimicrob Agents; 2020 Feb 15; 55(2):105864. PubMed ID: 31870598
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.